0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Variation in Inpatient Costs of Hematopoietic Cell Transplantation Among Transplant Centers in the United States FREE

Viengneesee Thao, MS1; Katy B. Kozhimannil, PhD1; Will Thomas, PhD2; Ezra Golberstein, PhD1
[+] Author Affiliations
1Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis
2Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis
JAMA Intern Med. 2014;174(8):1409-1412. doi:10.1001/jamainternmed.2014.2302.
Text Size: A A A
Published online

Hematopoietic cell transplantation (HCT) using the patient’s own (autologous) or a donor’s (allogeneic) HCT progenitor cells is a highly effective but costly therapy for life-threatening blood disorders and cancers. Despite the small number of annual procedures (20 000 a year in the United States), HCT hospitalization spending increased from $684 million to $1.3 billion between 2004 and 2007, placing it among the procedures with the most rapid spending increases.1 Those increases reflect rising procedure volume and rising hospitalization costs.1 Prior research2 on HCT costs has been limited to single-institution analyses. To quantify variation in costs of HCT across hospitals, we analyzed data from the Nationwide Inpatient Sample (NIS),3 the largest hospital database with charge information on all patients admitted to the sampled hospitals regardless of payer.

International Classification of Diseases, Ninth Revision (ICD-9) procedure codes were used to identify HCT hospitalizations in the 2008-2010 NIS database (autologous: 41.01, 41.04, 41.07, and 41.09; allogeneic: 41.02, 41.03, 41.05, 41.06, and 41.08). We analyzed data for adults from large-volume hospitals performing 30 or more HCT procedures (autologous or allogeneic). Smaller-volume hospitals were excluded because bed size was confounded with hospital HCT volume. We retained less than 5% of hospitals in the NIS survey; therefore, weighting was not needed. Patient age was categorized as adults (18-49 years) and older adults (≥50 years) owing to differences in transplant practices by age. We used ICD-9 diagnosis codes to construct Elixhauser comorbidity index scores.4

Cost was discounted to 2008 dollars and measured using an all-payer cost to charge ratio (when unavailable, the hospital’s group mean ratio was used). Costs for autologous and allogeneic HCT were modeled separately because of differences in indications, care, and outcomes. Linear regression was used to assess associations between costs and patient and hospital characteristics and to produce age-, sex-, diagnosis-, and comorbidity index–adjusted means. Costs were log-transformed for analysis and then transformed back for reporting. Statistical analyses were conducted with SAS, version 9.3 (SAS Institute Inc).

The adjusted mean cost for autologous HCT was $47 990. Cost varied by a factor of almost 4, from $21 280 to $81 830 (Figure). The highest–cost quintile hospitals had higher proportions of patients who were younger, were non-Hispanic white, were privately insured, and had a diagnosis of lymphoma compared with the lowest–cost quintile hospitals (Table) (P < .01 for all comparisons).

Place holder to copy figure label and caption
Figure.
Adjusted Ranked Hospital Mean Costs of Autologous and Allogeneic Hematopoietic Cell Transplantation (HCT), 2008-2010

Hospital geometric means are shown for autologous (n = 32) (A) and allogeneic (n = 22) (B) HCTs. The size of the plotting character is proportional to the hospital’s total volume of HCT cases. Hospitals in the highest and lowest quintile are indicated with squares. The lines across the graphs indicate the overall adjusted mean. Limit lines indicate 95% CI.

Graphic Jump Location
Table Graphic Jump LocationTable.  Demographics and Case Mix of HCT Patients

Overall adjusted mean allogeneic HCT cost was $86 580, and hospital means varied 5-fold ($26 580 to $146 090) (Figure). The highest–cost quintile hospitals performing allogeneic HCT had a larger percentage of privately insured patients, patients with 1 or more comorbidities, and fewer non-Hispanic white patients (Table).

Twenty-one hospitals performed both autologous and allogeneic HCTs. There was a significant cost correlation between the 2 procedures in these hospitals (r = 0.54, P = .01).

The costs of HCT vary significantly across hospitals in the United States. We were unable to determine how costs correlate with outcomes because the NIS does not contain postdischarge survival data. Future research should explore whether higher HCT costs correlate with better patient outcomes. The major strength of the present study is that the NIS data set allows comparison of HCT costs across hospitals nationally, which has not previously been performed. Limitations of the present study include the use of charge data to calculate costs and the sample size of US hospitals analyzed; HCT is performed in relatively few hospitals. Because the NIS database contains information only on inpatient settings, we could not consider variation in rehospitalizations, which should be a future research priority. Our findings warrant attention to payment policy and price transparency, especially in the context of health care reform, for their potential to reduce cost variation across hospitals.

Corresponding Author: Viengneesee Thao, MS, c/o Katy B. Kozhimannil, PhD, Division of Health Policy and Management, School of Public Health, University of Minnesota, 420 Delaware St SE, MMC 729, Minneapolis, MN 55455 (thaox634@umn.edu).

Published Online: June 16, 2014. doi:10.1001/jamainternmed.2014.2302.

Author Contributions: Ms Thao had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Thao, Golberstein.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Thao.

Critical revision of the manuscript for important intellectual content: Kozhimannil, Thomas, Golberstein.

Statistical analysis: Thao, Thomas, Golberstein.

Administrative, technical, or material support: Kozhimannil.

Study supervision: Kozhimannil, Golberstein.

Conflict of Interest Disclosures: Dr Kozhimannil’s work on this article was supported by the Building Interdisciplinary Research Careers in Women’s Health grant K12HD055887 from the Eunice Kennedy Shriver National Institutes of Child Health and Human Development, the Office of Research on Women’s Health, and the National Institute on Aging, at the National Institutes of Health, administered by the University of Minnesota Deborah E. Powell Center for Women’s Health. No other disclosures were reported.

Additional Contributions: Peiyin Hung, PhD candidate at the University of Minnesota, assisted with the discussion and review of the topic. There was no financial compensation.

Stranges  E, Russo  CA, Friedman  B. Procedures with the Most Rapidly Increasing Hospital Costs, 2004–2007: Statistical Brief #82. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Health Care Policy and Research; 2006. http://www.ncbi.nlm.nih.gov/books/NBK53597/. Accessed April 8, 2013.
Preussler  JM, Denzen  EM, Majhail  NS.  Costs and cost-effectiveness of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(11):1620-1628.
PubMed   |  Link to Article
Agency for Healthcare Research and Policy. Introduction to the HCUP Nationwide Inpatient Sample (NIS) 2010. http://www.hcup-us.ahrq.gov/db/nation/nis/NISIntroduction2010.pdf. Issued June 2010. Accessed April 8, 2013.
Elixhauser  A, Steiner  C, Harris  DR, Coffey  RM.  Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Figure.
Adjusted Ranked Hospital Mean Costs of Autologous and Allogeneic Hematopoietic Cell Transplantation (HCT), 2008-2010

Hospital geometric means are shown for autologous (n = 32) (A) and allogeneic (n = 22) (B) HCTs. The size of the plotting character is proportional to the hospital’s total volume of HCT cases. Hospitals in the highest and lowest quintile are indicated with squares. The lines across the graphs indicate the overall adjusted mean. Limit lines indicate 95% CI.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable.  Demographics and Case Mix of HCT Patients

References

Stranges  E, Russo  CA, Friedman  B. Procedures with the Most Rapidly Increasing Hospital Costs, 2004–2007: Statistical Brief #82. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Health Care Policy and Research; 2006. http://www.ncbi.nlm.nih.gov/books/NBK53597/. Accessed April 8, 2013.
Preussler  JM, Denzen  EM, Majhail  NS.  Costs and cost-effectiveness of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(11):1620-1628.
PubMed   |  Link to Article
Agency for Healthcare Research and Policy. Introduction to the HCUP Nationwide Inpatient Sample (NIS) 2010. http://www.hcup-us.ahrq.gov/db/nation/nis/NISIntroduction2010.pdf. Issued June 2010. Accessed April 8, 2013.
Elixhauser  A, Steiner  C, Harris  DR, Coffey  RM.  Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
PubMed   |  Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

436 Views
2 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
×